ideasIdea
Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review
Some drugs work on a genetic change whatever the cancer. When one regulator approves such a label, others should adopt it rather than demanding trials per cancer type.
Tumour-agnostic approvals (NTRK fusions, MSI-high, BRAF V600E, RET) rest on basket trials that some regulators have accepted and others have restricted to specific tumour types, producing labels that differ by region for the same evidence. Patients with rare tumours in restrictive regions are excluded. The proposal is a standing agreement that tumour-agnostic indications granted by one stringent regulator on basket-trial evidence are adopted by partners within 90 days, with a shared post-marketing registry to fill evidence gaps in rare histologies.
Hypothesis
Regional divergence in tumour-agnostic labels falls to zero for new approvals, and patients with rare cancers in adopting regions gain access a median of two years earlier than under current sequential review.
Rationale
Basket-trial evidence is inherently sparse per histology; asking for more per-tumour data from each region is a demand that cannot be met and simply denies access. A shared registry produces better evidence than any region could alone.
What would test it
Document current divergence for the existing tumour-agnostic indications across ten regulators; pilot reciprocal adoption for the next two tumour-agnostic approvals with a shared registry.
Maturity
speculative
Who has to act
regulator
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.